Liafensine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Liafensine
Liafensine.svg
Clinical data
Routes of
administration
Oral
ATC code
  • None
Legal status
Legal status
  • Development terminated
Identifiers
CAS Number
PubChem CID
ChemSpider
KEGG
Chemical and physical data
Formula C24H22N4
Molar mass 366.458 g/mol
3D model (JSmol)

Liafensine (BMS-820836) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) which was under development by Bristol-Myers Squibb for the treatment of major depressive disorder.[1] Though it demonstrated comparable effectiveness to escitalopram and duloxetine in phase II clinical trials, development was terminated in 2013 because liafensine failed to show superior effectiveness relative to these drugs, a decision that was made likely based on its increased capacity for side effects as well as potential for abuse.[1]

See also[edit]

References[edit]

  1. ^ a b "Digest". Progress in Neurology and Psychiatry. 17 (5): 41–43. 2013. ISSN 1367-7543. doi:10.1002/pnp.305.